ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic develop...
Leadership
Jason W. Lettmann
CEO & Director
Harish Shantharam C.F.A.
Chief Financial Officer
Shelly Wong CPA
Senior VP of Finance & Chief Accounting Officer
Barbara J. Klencke M.D.
Chief Medical Officer
Jeff E. Knight M.P.H.
Chief Development & Operating Officer
Athanasios Tsiatis M.D.
Senior Vice President of Clinical Development
Lin Yeong-Liang M.D., M.S.
Senior Vice President of Drug Safety & Pharmacovigilance
Lisa Sauer
Senior Vice President of Regulatory Affairs & Quality Assurance
